Is Tambocor still available?
From 1 September, 2019, Flecainide BNM 50 mg immediate release tablets will be funded and will replace Tambocor over a five-month transition period. From 1 February, 2020, Flecainide BNM will be the only funded brand of flecainide 50 mg tablets (until at least 30 June, 2022) and Tambocor will not be subsidised.
Does flecainide have another name?
Flecainide is available under the following different brand names: Tambocor.
What is the generic name for Tambocor?
GENERIC NAME: FLECAINIDE – ORAL (fleck-UH-nide)
What is Tambocor 100mg used for?
It is used to restore normal heart rhythm and maintain a regular, steady heartbeat. It is also used to prevent certain types of irregular heartbeat from returning (such as atrial fibrillation). Flecainide is known as an anti-arrhythmic drug.
What medication can replace flecainide?
Is there an alternative to flecainide? There are many other antiarrhythmic medications that treat the same conditions as flecainide, such as propafenone, sotalol, or amiodarone.
Does flecainide treat SVT?
Conclusion: This preliminary experience indicates that flecainide is well tolerated and effective as first-line treatment for paroxysmal SVT in newborns without structural heart disease.
How long can I stay on flecainide?
In the acute setting, flecainide is recommended for pharmacological cardioversion of PAF of no more than 7 days’ duration, and there is also strong evidence supporting the use of flecainide prior to electrical cardioversion.
Who should not take flecainide?
You should not use flecainide if you are allergic to it, or if: you have a serious heart condition such as bundle branch block or AV block (unless you have a pacemaker); or. your heart cannot pump blood properly.
Does flecainide slow heart rate?
Flecainide belongs to the group of medicines known as antiarrhythmics. It works directly on the heart tissue and will slow the nerve impulses in the heart. This helps keep the heart rhythm normal.
What are the adverse effects of Tambocor (flecainide)?
Adverse effects reported for TAMBOCOR (flecainide) , described in detail in the Warnings section, were new or worsened arrhythmias which occurred in 1% of 108 patients with PSVT and in 7% of 117 patients with PAF; and new or exacerbated ventricular arrhythmias which occurred in 7% of 1330 patients with PVCs, non-sustained or sustained VT.
What is the mortality and morbidity associated with Tambocor?
SIDE EFFECTS In post-myocardial infarction patients with asymptomatic PVCs and non-sustained ventricular tachycardia, TAMBOCOR (flecainide) therapy was found to be associated with a 5.1% rate of death and non-fatal cardiac arrest, compared with a 2.3% rate in a matched placebo group.
When should Tambocor (flecainide) be initiated in patients with VT?
For patients with sustained VT, no matter what their cardiac status, TAMBOCOR (flecainide) , like other antiarrhythmics, should be initiated in-hospital with rhythm monitoring. Flecainide has a long half-life (12 to 27 hours in patients).
What is flecainide used to treat?
Flecainide is used to prevent or treat irregular heartbeats (arrhythmias) such as paroxysmal supraventricular tachycardia (PSVT) and paroxysmal atrial fibrillation/flutter (PAF).
